Chromocell Therapeutics ( NYSE: CHRO ) on Wednesday announced a stock repurchase plan of up to $250,000 of Chromocell’s common stock, which represents about 23% of the non-affiliate float based on the closing price of the company’s common stock as of August 6. CHRO -22.38% premarket to $0.
78. Source: Press Release More on Chromocell Therapeutics Corporation Financial information for Chromocell Therapeutics Corporation.
